Of the hazards of bringing home a mammoth. Or two. Woho!!
Out of the woods with the kids. I'll have to relisten to that many times...
But my key take away for the moment...
- This is going to be even larger then expected.
- We're going to end up owning an even larger share of the mammoths, at the price of a somewhat longer road.
- It's worth taking a few more months / Qs to wait for the real data from the open label trials, and to negociate with the many regulatory agencies and do a single well designed trial, then rushing it.
- Expect many new growing-value indications in between to help us ramp up the revenue stream and own a larger partof the largest indications.
- Confirmation that Q4 trials results / BLA filing will be pivotal moment.
- Confirmation that next summer will be even larger most pivotal moment of PLI history.
- My model will have to be updated with some delay (2020 rather than 2019) but much much more value.
I plan to update my valuation after that analyst conference somewhere in the late september / early october time frame.
But I'll come back in the next days after I've upgraded the transcript, with more of what I understand out of it. But the most important feeling I get for the first time with Prometic, is : this company is being built to become a top 10 WW pharma, not being bought. (Just think of the comment about the many different PBI compounds for the many different indications, this is clearly so to reduce the risk of one asset being a too easy too broad target, ending up being necessarily under valued).
Lord, considering what's on my plate on the EEStor side, this Q4 is going to be anything but quiet! :-P
Enjoy the last next weeks of calm summer.
:-)
FD